Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery H1 Revenues Fall 14 Percent

NEW YORK — Horizon Discovery Group reported on Monday a 14 percent year-over-year drop in revenues for the first half of 2020 as a reduction in academic research due to the ongoing SARS-CoV-2 pandemic bit into sales of the company's reagent offerings.

For the six-month period ended June 30, Horizon's revenues fell to £22.4 million ($29.3 million) from £26.1 million a year earlier. On a constant currency basis, the gene editing and gene modulation technologies firm's revenues were down nearly 16 percent to £22.0 million.

First-half revenues from Horizon's research reagents unit dropped 15 percent to £16.0 million from £18.9 million. Horizon's reagents operations now include diagnostics following its recent decision to discontinue the manufacture of custom cell line-derived reference standards to focus on higher volume off-the-shelf and made-to-order reference standards.

Bioproduction revenues, meanwhile, fell 29 percent to £2.0 million from £2.8 million, while screening revenues ticked up 2 percent to £4.4 million from £4.3 million in the same period last year. Horizon has yet to record revenues from its newly established base editing unit, which is developing a gene-editing technology exclusively licensed from Rutgers University.

"We were affected by COVID-19 and the widespread lockdown in the second quarter of the year, which resulted in a rapid reduction in academic research work, leading to a marked reduction in orders for our research reagents business unit in particular," Horizon CEO Terry Pizzie said in a statement.

"Whilst in H2 2020 we will not make up the revenues lost in our research reagents business during Q2 and have experienced delays to evaluations in bioproduction, COVID-19 has also positively impacted demand for our services in screening as our biopharma customers embraced outsourcing to meet their own business challenges during the pandemic," he noted.

Cambridge, UK-based Horizon's H1 net loss climbed to £9.4 million, or 6.1 pence per share, versus £5.6 million, or 3.7 pence per share, in the year-ago period.

Its R&D costs were up almost 9 percent to £7.5 million from £6.9 million while SG&A expenses rose 13 percent to £19.3 million from £17.1 million, in part due to Horizon's preparations for a listing on the Nasdaq and the ramping up of its base editing unit operations.

At the end of June, Horizon had cash and cash equivalents totaling £23.6 million.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.